The Role of Interventional Radiology in the Management of Pancreatic Pathologies

Ghali Salahia1  Sook Cheng Chin2  Ian Zealley2  Richard D. White1

1Department of Radiology, University Hospital of Wales, Cardiff, United Kingdom
2Department of Radiology, Ninewells Hospital, Dundee, United Kingdom

Address for correspondence  Ghali Salahia, MD, MBA, Department of Radiology, University Hospital of Wales, Heath Park Way, Cardiff, CF14 4XW, United Kingdom (e-mail: gsalahia@hotmail.com).


Abstract

Pancreatic pathologies are varied and wide-ranging, and a multidisciplinary approach is essential for effective diagnosis and management. We describe image-guided percutaneous (nonendoscopic) interventions in the management of pancreatic disease, with emphasis on inflammatory and neoplastic pancreatic pathologies and on the transplanted pancreas. Image-guided treatments for the complications of pancreatitis include percutaneous interventions on simple and complex peripancreatic collections, pseudocysts, and fistulas. Vascular interventions predominantly focus on the treatment of pseudoaneurysms, hemorrhagic pseudocysts, and arteriovenous malformations. Emerging ablative techniques for pancreatic cancer are promising and include percutaneous radiofrequency ablation, microwave ablation, irreversible electroporation, and electrochemotherapy. Image-guided interventions on the transplanted pancreas commonly include percutaneous biopsy and drainage in addition to endovascular treatments of vascular complications.

Keywords

► interventional radiology
► pancreatic cancer
► pancreatic transplant
► pancreatitis
► peripancreatic collection

Introduction

Approximately 20% of patients with acute pancreatitis will develop complications that require intervention.1 These can be classified into vascular and nonvascular complications:

• Nonvascular complications include collections, bowel complications, and pancreatic fistulas.

• Vascular complications include peripancreatic arterial and venous pseudoaneurysms, venous thrombosis, and arteriovenous malformations (AVMs).3

Pancreatic adenocarcinoma is the 12th most common malignancy and the 7th leading cause of cancer-related mortality globally.4 Most patients present late with either locally extensive or metastatic disease.5 The aggressive nature, late presentation, and lack of effective therapies all contribute to the poor prognosis. Patients with more advanced disease will typically undergo either endoscopic ultrasound (US) or interventional radiology-guided interventions to deliver either palliative or preoperative care.4

Pancreas transplantation offers diabetic patients the prospect of glycemic control free of exogenous insulin administration, with a significant improvement in quality of life and reduction in diabetes-associated complications.6 Surgery can, however, be complicated by a high rate of early technical failure.7 Percutaneous and endovascular interventions are increasingly performed for the diagnosis of rejection and the treatment of vascular complications.

Nonvascular Interventions

Drainage of Peripancreatic Collection

Intra-abdominal collections and abscesses are the most common complication following acute pancreatitis.8 Collections are classified according to the revised Atlanta Classification into acute peripancreatic fluid collections, pseudocysts, acute necrotic collections, and walled-off necrosis9,10 (► Fig. 1). Symptomatic intra-abdominal collections require imaging-guided drainage. When a collection is readily
visualized on US, US-guided percutaneous drainage placement is generally the preferred choice as US is less expensive, allows for real-time monitoring of the needle placement, and is free from ionizing radiation. However, the combination of US and fluoroscopy can improve on this by facilitating safe needle puncture using US guidance followed by optimal drain positioning using fluoroscopic guidance.

Infected pancreatic necrosis is often poorly marginated and nonenhanced and may contain bubbles of gas. However, these features are not always present, and necrotic collections without signs of infection at CT should be considered sterile until proven otherwise. Percutaneous drainage is generally avoided in this context due to the potential risk of introducing infection. Deteriorating patients with high

Fig. 1 (A) Acute peripancreatic fluid collection (green arrow). (B) Multiple pseudocysts (yellow arrows) in the context of acute on chronic pancreatitis (note the pancreatic calcifications). (C) Acute necrotic collection (note absent enhancement of the pancreatic head). (D) Percutaneously drained walled-off necrosis (blue arrow indicate the wall). (E) This had been subsequently infected (note the presence of gas).
clinical suspicion of infection may benefit from US-guided aspiration to rule out an infected pancreatic necrosis. When infected necrosis is present, large-bore or multiple percutaneous drainage catheters should be sited in the collection as a bridge or as an alternative to surgical debridement.12

Guidelines from 2013 by the International Association of Pancreatology and the American Pancreatic Association advise postponing all forms of invasive intervention in patients with infected necrosis, preferably until 4 weeks after the onset of disease.13 The rationale behind this is fourfold. First, antibiotics alone might be sufficient as treatment. Second, diagnosing infected necrotizing pancreatitis is often easier in the later stages of the disease, when all other sources of infection or systemic inflammatory response have been ruled out. Third, catheter drainage is typically easier once the collection has become more liquefied and the stage of walled-off necrosis has been reached. Fourth, endoscopic transluminal drainage requires a walled-off collection.

In theory, it is not always necessary to wait several weeks until full encapsulation of peripancreatic collections and percutaneous drainage can be performed safely and successfully in the first weeks after the onset of disease.14 If there is no technical reason for postponing catheter drainage, patients with infected necrotizing pancreatitis might benefit from earlier catheter drainage in terms of reducing the rate of complications and length of hospital stay. This is also the case in the context of abdominal compartment syndrome. More recently, the Dutch Pancreatitis Study Group is undertaking a randomized controlled trial (POINTER [postponed or immediate drainage of infected necrotizing pancreatitis]) that will compare immediate and delayed catheter drainage in an attempt to further improve the outcome of these severely ill patients.15

When a collection is located deep in the abdomen or is poorly visualized on US, computed tomography (CT) offers adequate guidance to allow safe placement of percutaneous drains.16

After placement and aspiration of fluid, self-locking pigtail drains of size 8 to 12 Fr are left in place and irrigated with 10 to 20 mL of sterile saline three times daily. Catheters can be upsized to a maximum of 28 F, as the clinical situation evolves if smaller drains prove inadequate.8

External drainage of peripancreatic collections may fail in the setting of abnormal pancreatic ductal anatomy. In a study by Nealon et al, there was a statistically significant difference in successful percutaneous drainage between patients with normal pancreatic duct anatomy and those with a pancreatic duct stricture or duct disconnection.17 Drainage failed to permanently resolve the collection in half of the patients with duct strictures and was uniformly unsuccessful in patients with ductal disconnection or occlusion.

The incidence of cyst–cutaneous fistula formation is reportedly as high as 50% in certain settings18; therefore internal transgastric drainage is preferable in situations in which a persistent pseudocyst is being driven by a persisting pancreatic duct fistula (Fig. 2).

**Fistula Treatment**

Pancreatic fistulas may complicate pancreatic surgery or necrotizing pancreatitis.22 They can communicate with bowel loops, liver, or other adjacent viscera.23

The incidence of gastrointestinal fistulation following acute pancreatitis is reportedly 3 to 47%, with an associated increase in mortality of up to 34.7% in those with pancreatic colonic fistulae.24

**Fig. 2** CT-guided guided drainage of peripancreatic collection through a right posterior approach.

**Pseudocyst Gastrostomy**

Iatrogenic communication between a pseudocyst and hollow viscus can be formed to enable drainage (Fig. 3). Internal gastric drainage of pancreatic pseudocysts is now commonly performed under endoscopic US guidance.19 CT-guided percutaneous technique cannot regularly provide an adequately wide cystogastrostomy opening.11 Surgical cystogastrostomy is usually reserved for necrotic collections that do not abut the gastrointestinal tract and may be found in the retroperitoneal space.10

The percutaneous approach typically necessitates two stages, with the pseudocyst initially being drained percutaneously through a transgastric route as a temporary bridge before converting into an internal cystogastrostomy drainage through a double-J stent or by pushing the percutaneous drain into the stomach.20

There is no consensus about the duration of drainage through pseudocyst gastrostomy. After the introduction of this technique in 1984, pigtail catheter removal was initially advised after 3 months. The technique has since evolved such that the catheter is left in situ for at least 1 year to more than 3 years if there is a concern that catheter removal would lead to symptomatic recurrence. Catheter removal by forceps during routine gastroscopy in the outpatient setting has been reported.21

Technical success in percutaneous catheter placement is greater than 90%, with an immediate complication rate of around 6% and a mortality rate of 1%.18 Secondary infection with abscess formation is not uncommon, occurring in around 11%.21 Complete resolution of the pseudocyst with this method has been reported in at least 88% of cases.18
In the presence of a fluid collection, percutaneous drainage can treat the collection, and this may occasionally lead to spontaneous resolution of the fistula. If the main component of a fistula is of biliary origin, transhepatic biliary drain insertion can lead to fistula closure by diverting bile from the site of the fistula. In cases with persisting biliary leak, the placement of an occlusion balloon above the fistula may divert biliary flow away from the fistula.

Direct fistula embolization has been found to be effective, with access gained through the tract of a previous surgical drain, through an image-guided percutaneous drain, or through a transhepatic approach. Once the fistula site has been reached, different materials may be used to facilitate closure, including ethanol, particles, or glue.

Percutaneous Necrosectomy

Following liquefaction and encapsulation of necrotic pancreatic tissue, persistent infection of these cavities despite percutaneous drainage has been ascribed to the formation and infection of sequestered solid necrotic tissue that is presumed to be inaccessible to antibiotics. Surgical necrosectomy has historically been the mainstay of treatment for symptomatic patients. However, in the current era, when percutaneous or endoscopic drainage of pancreatic abscess/infected necrotic collection fails, there may be a role for percutaneous necrosectomy in patients who are not fit for open or laparoscopic drainage.

The procedure is performed by exchanging a preexisting left flank drain for a guidewire. Right-sided or transperitoneal drainage is also possible. A low-compliance balloon dilator is inserted into the collection and dilated to up to 30 Fr. Access to the cavity is achieved by passing a nephroscope (or similar) through a sheath, which allows debridement under direct vision. The nephroscope has an operating channel that permits standard (5 mm) laparoscopic graspers as well as an irrigation/suction channel. High-flow lavage promotes initial evacuation of pus and liquefied necrotic material, exposing residual black or gray devascularized pancreatic necrosis and peripancreatic fat, which, if loose, is extracted in a piecemeal fashion until, after several procedures, a cavity lined by viable granulation tissue is created. At the end of the procedure, an 8-Fr catheter sutured to a 24-Fr drain is passed into the cavity to allow continuous postoperative lavage of warm 0.9% normal saline. Chemically assisted debridement with hydrogen peroxide has been reported during endoscopic drainage.

The necrotic pancreatic body and fatty tissue can also be fragmented using a snare catheter (LASSOS, Osypka Medical, Rheinfelden, Germany) and a Dormia basket advanced through the percutaneous sheath. Others described the use of a 14- to 16-Fr Malecot catheter (CR Bard Inc., Covington, Georgia) for debridement by twisting it repeatedly inside the collection. An endoscopic clamp through an appropriately sized introducer sheath can also be used percutaneously for the same purpose.

Vascular Interventions

Endovascular Treatment of Bleeding

Peripancreatic Pseudoaneurysm Embolization

Pseudoaneurysms develop in approximately 4 to 8% of patients with chronic pancreatitis and less frequently in the context of acute pancreatitis. They most commonly affect the splenic artery followed by gastroduodenal, pancreaticoduodenal, and hepatic arteries. The etiology is attributed to an enzymatic insult to peripancreatic arteries or erosion of a pseudocyst into adjacent visceral arteries. Although rupture of a pseudoaneurysm is rare, it is a serious complication, potentially resulting in massive hemorrhage with concomitant significant clinical deterioration. A mortality rate of up to 37% has been reported.

Early detection of pseudoaneurysms is important to prevent subsequent rupture and catastrophic outcomes. Abdominopelvic CT is the imaging modality of choice in patients with complicated pancreatitis. Images are obtained following intravenous administration of 100 to 150 mL of iodinated contrast material at a rate of
3.5 mL/second or higher using a mechanical power injector. Craniocaudal pancreatic scanning is performed during breath-hold and commenced 30 to 50 seconds from the start of the contrast injection (pancreatic parenchymal phase). This imaging technique is suitable for the detection and follow-up of nonvascular complications of pancreatitis, as well as venous and most arterial complications. Detection of more subtle arterial complications (small pseudoaneurysms and subtle arterial hemorrhage) may require confirmation with CT angiography or catheter angiography in indeterminate cases.

Several techniques for the endovascular treatment of pseudoaneurysms have been reported in the literature using various embolization agents, such as embolization of the aneurysm neck, embolization proximal to the pseudoaneurysm, and embolization of vessels both distal and proximal to the pseudoaneurysm, the so-called “isolation” or “sandwich” technique. Preference for a specific therapeutic approach must take into consideration several factors such as the anatomical location of the affected vessel, the nature of the artery (expendable with extensive collateral circulation vs. nonexpendable), the size of pseudoaneurysm sac, and the patient’s hemodynamic status.

Although embolization of the aneurysmal neck can spare blood flow in the parent artery, infusion of the embolization material may induce rupture due to the fragility of the aneurysm wall. In addition, this technique increases the risk of migration of embolic materials. Embolization at a point proximal to the pseudoaneurysm is generally a more straightforward technique but carries a higher risk of failure secondary to blood flow from collateral vessels. It is for this reason that the isolation technique using aneurysm coils is considered the optimal endovascular approach in patients with visceral artery pseudoaneurysms. In a series of 37 patients with visceral artery pseudoaneurysms embolized with coils using the isolation technique, 32 patients had confirmed complete resolution of pseudoaneurysms on CT scans obtained at 1 day postprocedure, although two cases of recurrence were seen during follow-up.

Several recent studies have reported the effectiveness of transcatheter arterial embolization with N-butyl cyanoacrylate (NBCA) glue. According to Toyoda et al, the hemostasis ratios for acute gastroduodenal bleeding treated by transcatheter arterial embolization with NBCA and transcatheter arterial embolization with gelatin sponge particles and/or coils are 85.7 and 78.3%, respectively. When the isolation technique cannot be performed, NBCA embolization is recommended as an alternative.

Stent grafts can be used to exclude pseudoaneurysm if the neck is unfavorable or when the parent artery is nonexpendable (e.g., the superior mesenteric artery [SMA]). Bovine thrombin is also an option as an endovascular embolic agent. Although an off-label use of the thrombin, it has also been used for percutaneous direct puncture and embolization of pseudoaneurysm by injecting thrombin into the pseudoaneurysm as well as the surrounding fluid collection percutaneously under CT guidance.

Other materials used for percutaneous direct puncture for pancreatitis-related pseudoaneurysm treatment include glue, Gelfoam, PVA (polyvinyl alcohol) particles, and coils, with variable success rates.

If there is a concern that high-velocity blood flow will increase the risk of nontarget embolization when using liquid embolic agents and coils, vascular occlusion plugs may be useful, providing a well-controlled and stable occlusion. Vascular occlusion plugs also have the advantage of having a more flexible delivery system when compared with stent placement.
glands, and recent advances in technology have seen the introduction of plugs deliverable through a microcatheter.\textsuperscript{13}

Overall, transarterial embolization of pancreatitis-related pseudoaneurysms is relatively safe and effective. Recurrence or new pseudoaneurysm formation rates are low and usually occur within 6 months of embolization.\textsuperscript{49}

Venous pseudoaneurysms are an extremely rare complication of pancreatitis, with a handful of known cases following pancreatic surgery or abdominal trauma.\textsuperscript{30,51} Spontaneous resolution has been reported, with a natural progression to thrombosis. In another case, a posttraumatic superior mesenteric vein pseudoaneurysm was treated with coiling through a percutaneous transhepatic approach.\textsuperscript{51}

Ruptured Pseudoaneurysm into a Pseudocyst (Hemosuccus Pancreaticus)

A peripancreatic pseudoaneurysm may rarely rupture into a pancreatic pseudocyst, with hemorrhage traveling through the pancreatic duct into the gastrointestinal tract through the ampulla of Vater (\textsuperscript{\textbullet}Fig. 5). This condition, “hemosuccus pancreaticus” (HP), was first reported by Sandblom in 1970, with an estimated incidence of 1 in 1,500 cases of acute gastrointestinal hemorrhage.\textsuperscript{52}

The most common cause of HP is chronic recurrent pancreatitis related to chronic alcoholism, which results in pancreatic pseudocyst formation.\textsuperscript{51} The peripancreatic vessels most commonly involved are splenic, gastroduodenal, pancreaticoduodenal, gastric, and hepatic arteries.\textsuperscript{54}

The most common symptoms are melena and upper abdominal pain. Visualization of spurting blood from the ampulla of Vater is diagnostic.\textsuperscript{55} However, because of the typically intermittent nature of the bleeding, and difficulty visualizing bleeding from the ampulla of Vater using an end-viewing endoscope, upper gastrointestinal endoscopy establishes the diagnosis in only 30% of cases.\textsuperscript{56} Diagnosis can often be challenging with only a suspicion of a pseudoaneurysm on cross-sectional imaging. Treatment approach is similar to other peripancreatic pseudoaneurysms.

Hemorrhagic Pseudocysts

As previously described, pseudoaneurysms can be free-standing or can be located within a pseudocyst. Furthermore, pseudoaneurysms can erode into an adjacent artery, forming an expanding hemorrhagic cyst that can rupture into an adjacent hollow organ, or can communicate with the pancreatic duct producing HP.\textsuperscript{52}

The overall incidence of bleeding associated with pancreatitis is not well established. The prevalence of bleeding pseudoaneurysms ranges from 2 to 31%.\textsuperscript{32,57} While most life-threatening hemorrhage is arterial in origin, venous bleeding can occur, as well as massive diffuse small vessel hemorrhage associated with pancreatic necrosis.

Spontaneous abdominal hemorrhage can develop at any time in patients with a history of pancreatitis but is often a late complication, with a mean time of occurrence of 2.3 years.\textsuperscript{52} In Balthazar and Fisher’s series of 16 patients with pancreatitis-related hemorrhage, bleeding was secondary to pseudoaneurysms in 61%, hemorrhagic pseudocysts in 19.5%, and severe capillary and venous bleeding associated with pancreatic necrosis in 19.5%.

It is not always possible to identify a single culprit vessel on CT or angiography; hence, surgical treatment is suggested in case of severe venous or diffuse capillary bleeding, hemorrhagic pseudocysts, and unsuccessful embolization (\textsuperscript{\textbullet}Fig. 6).

Pancreatic Arteriovenous Malformation Embolization

Pancreatic AVM (P-AVM) is rare (~90 cases have been reported).\textsuperscript{14} They may be congenital in association with hereditary hemorrhagic telangiectasia or Osler–Weber–Rendu’s disease. They may also be posttraumatic or occur following pancreatic transplantation, neoplasm, or inflammation.\textsuperscript{59}

The majority of patients with P-AVM remain asymptomatic. Gastrointestinal hemorrhage may occur from a ruptured varix secondary to portal hypertension or direct erosion of the AVM into the pancreatic/bile duct or through the adjacent intestinal mucosa as a duodenal ulcer.\textsuperscript{26}

The pancreatic head is most commonly involved (56%) followed by the body and tail (33%), with the entire pancreas involved in 7%. The definitive treatment for P-AVM has traditionally been surgical resection.\textsuperscript{60} However, Bruno et al described a case of a P-AVM communicating the splenic artery, the superior pancreatic artery, and the splenic vein.\textsuperscript{61} This was treated with coil embolization of the two feeding arteries, with no significant filling of the portal vein on subsequent angiography.

Oncological Interventions

Percutaneous Biopsy

Biopsy can be performed intraoperatively, endoscopically, or percutaneously with CT or US guidance.\textsuperscript{62} Percutaneous imaging-guided fine needle aspiration (FNA) has been in use since the 1970s, but it can be challenging to establish a definitive diagnosis of pancreatic adenocarcinoma from cytology samples. As an alternative, image-guided percutaneous biopsy of the pancreas with an automated core biopsy needle has become more commonly used.\textsuperscript{83}

A retrospective study by Yang et al reviewed a sampling of 88 pancreatic masses: 13 underwent FNA only, 60 underwent core needle biopsy only, and 15 underwent both.\textsuperscript{64} The diagnostic accuracy of core biopsy alone and both core biopsy and FNA was comparable at 93.3% and was marginally lower for patients who underwent FNA alone (92.3%). The negative predictive value was 57% overall for all biopsies. This is too low for a reliable exclusion of the presence of pancreatic malignancy and suggests that negative results of percutaneous biopsy, whether core or FNA, should be viewed with caution.

Percutaneous Transhepatic Biliary Drainage

Malignant biliary obstruction is most commonly associated with pancreatic carcinoma, developing in 70 to 90% of patients and typically leading to jaundice, pruritus, hepatocellular dysfunction, malabsorption coagulopathy, and cholangitis.\textsuperscript{65} Biliary decompression may be achieved by endoscopic retrograde cholangiopancreatography (ERCP)
Fig. 5 Coronal reformatted CT (computed tomography) in (A) arterial and (B) portal venous phases in an 89-year-old male patient with massive upper gastrointestinal (GI) hemorrhage. There is evidence of rupture of splenic artery pseudoaneurysm (yellow arrow) into a pancreatic tail pseudocyst (blue arrows). The GI hemorrhage was presumed to be coming from a pseudocyst eroding through the stomach (green arrow). (C, D) This was treated successfully with coil embolization of the splenic artery.

Fig. 6 A 28-year-old male with previous gallstone pancreatitis underwent a follow-up MRI (magnetic resonance imaging) for a known pseudocyst. (A) Coronal FIESTA (fast imaging employing steady-state acquisition) sequence demonstrates isointense material within pancreatic pseudocyst suspicious of hemorrhage. (B) Arterial phase coronal CT (computed tomography) shows high-density material within the cyst in keeping with hemorrhage; however, no pseudoaneurysm was seen. The patient underwent catheter angiography, which did not reveal a site of active contrast extravasation or a pseudoaneurysm (not shown).
or through percutaneous transhepatic biliary drainage (PTBD).

Endoscopic insertion of plastic or metal stents is technically successful in approximately 90 to 95% of malignant biliary obstruction cases. If ERCP fails due to inaccessible papilla due to congenital or surgically altered anatomy, failed cannulation, or the presence of severe tumor-induced strictureting of the bile duct and/or duodenum, PTBD can be undertaken. An intrahepatic bile duct branch is accessed (under fluoroscopic and/or US guidance) with an 18- to 22-gauge needle followed by a 0.018-inch guidewire. Puncture with a smaller caliber (22-gauge) needle has been shown to be safer in patients without intrahepatic bile duct dilatation. Intraductal position is confirmed by a backflow of bile or by fluoroscopic visualization of injected contrast. The 0.018-inch guidewire is exchanged for a 0.035-inch guidewire. Depending on operator preference, an access sheath (generally 6 Fr or larger) may be used and the stricture crossed using a catheter and guidewire. After crossing the stricture, the wire is exchanged for a stiff wire. The drainage catheter or stent is then deployed. Internal/external drains must have side holes on each side of the obstruction but not extending into the liver parenchyma as this leads to bile leak. Stents must completely cover the lesion.

Drainage is successful in approximately 95% of patients with dilated intrahepatic bile ducts but only 70% of patients with nondilated ducts. Results from a national audit of 833 patients in the United Kingdom who had undergone PTBD in 2009 showed high immediate technical success for drainage and stenting (>95%). Minor complications occurred in 26.0% of patients, the most common being pain (14.3%), sepsis (7.7%), and hemorrhage (4.5%). Major complications occurred in 7.9% of patients, the most common being hemorrhage (3.5%), renal failure (1.8%), and sepsis (1.6%). Data also showed a high inhospital mortality rate (25%) due to dramatic direct portal venous gastrointestinal hemorrhage and acute renal failure. In a later study by Girelli et al, 50 patients with locally advanced pancreatic cancer were treated by open cool-tip RFA, with high mortality rate (25%) due to dramatic direct portal venous gastrointestinal hemorrhage and acute renal failure.

Radiofrequency Ablation

Wu et al first described open surgical RFA for unresectable pancreatic tumors. Sixteen patients with unresectable pancreatic cancer were treated by open cool-tip RFA, with high mortality rate (25%) due to dramatic direct portal venous gastrointestinal hemorrhage and acute renal failure. RFA was the only treatment in 19 patients. RFA was combined with biliary and gastric bypass in 19 patients, gastric bypass alone in 8, biliary bypass alone in 3, and pancreaticojejunostomy in 1. There was only one case of 30-day mortality in this series. The reported RFA-related complications were two cases of pancreatic fistulas and four cases of portal vein thrombosis.

Microwave Ablation

High-frequency (2.45-GHz) microwave ablation (MWA) for the treatment of unresectable and nonmetastatic locally advanced pancreatic cancer has been trialed by Lygidakis et al. It has been suggested as a local effective procedure that is feasible and safe, with acceptable minor complications.
in locally advanced pancreatic tumors, which can be used as part of a palliative or multimodality treatment.

However, the feasibility and safety of percutaneous MWA approach require further evaluation.\textsuperscript{72}

Percutaneous Irreversible Electroporation
This is a nonthermal ablative technology first described in 2009 by Garcia et al.\textsuperscript{73} It uses high-voltage low-energy direct current through electrodes placed into the pancreas percutaneously under CT guidance to create permanent pores in the cell membrane, leading to cell death.

The largest retrospective review of patients with pancreatic adenocarcinoma who underwent percutaneous IRE was conducted at Miami Cancer Institute in 2014.\textsuperscript{74} The study included 50 patients with biopsy-proven unresectable pancreatic cancer. The overall survival for the entire cohort from the date of IRE was 14.5 months (95\% confidence interval: 10.4–18.6 months). Complications occurred in 20\% of patients, including pancreatitis, pain, sepsis, and gastric leak.

Electrochemotherapy
ECT is an electroporation-based therapy with an already established place in the treatment of cutaneous and liver tumors.

Only one case series (clinical phase I/II) of intraoperative pancreatic ECT with 13 patients has been reported.\textsuperscript{75} Intraoperative electrodes were inserted with US guidance into and around the tumor followed by an intravenous bolus of bleomycin (15,000 IU/m\textsuperscript{2}) and subsequent electric pulses by an electric pulse generator. Treatment was completed within the time window of 8 to 28 minutes after the end of the bleomycin bolus. This time window ensured the maximum concentration of drug within the lesion. No intra- or postoperative serious adverse events related to ECT were observed.\textsuperscript{75}

Further research is being undertaken to evaluate the safety and efficacy of this technique in pancreatic cancer treatment.\textsuperscript{76}

Interventional Radiology for the Transplanted Pancreas
Pancreas transplantation is most frequently performed in conjunction with kidney transplantation in the cases of end-stage renal failure secondary to type 1 diabetes. This procedure is known as simultaneous pancreas–kidney transplantation.\textsuperscript{1}

The pancreatic exocrine enzymes can be drained directly into the enteric circulation by constructing a side-to-side anastomosis between the donor duodenum and the recipient small bowel or recipient bladder (→ Fig. 8).

Vascular Complications of the Transplanted Pancreas
Vascular complications of the transplanted pancreas can be broadly divided into thrombosis, stenosis, hemorrhage, aneurysms, and AVM.\textsuperscript{77,78}

Imaging investigations usually start with a Doppler study to determine the presence of waveform tracings from the implicated vessel. Suspicious duplex US findings should be evaluated with contrast-enhanced CT or contrast-enhanced magnetic resonance imaging (MRI); these noninvasive modalities have largely replaced catheter angiography as means of diagnosis, although the latter remains the gold standard for the assessment of pancreatic artery complications following transplant.\textsuperscript{78} One advantage of catheter angiography is the ability to proceed directly to endovascular treatment in the same procedure.

Transplant Artery Thrombosis
This is the most severe posttransplantation vascular complication predisposing the graft to dysfunction and necrosis.\textsuperscript{1} It most commonly occurs within the first 3 months following transplantation.

The symptoms of thrombosis include unexplained hyperglycemia, tenderness over the graft, graft enlargement, and, in bladder-drained grafts, hematuria and decreased urinary amylase.\textsuperscript{6}

Accurate and expedient imaging diagnosis of arterial thrombosis is essential because early revascularization...
with or without thrombectomy may salvage the graft.\(^7\)

Predisposing factors include prolonged cold ischemia, prolonged back-table preparation, graft rejection, pancreatitis, stump thrombi, and vessel trauma.\(^7\)

Complications of pancreas graft thrombosis include graft dysfunction, leakage of pancreatic secretions, pancreatitis, necrosis, and sepsis. Prompt surgical exploration is often required.\(^6\)

Transplant Artery Stenosis

Arterial stenosis following pancreas transplantation is less common than arterial thrombosis and is typically an early posttransplantation complication.\(^1\) Predisposing factors include rejection clamp injury, faulty surgical technique, catheter-induced trauma, and disruption of the vasa vasorum.\(^8\) This is usually assessed with arterial Doppler, with a peak systolic velocity of 2 m/second or greater being suggestive of an arterial stenosis greater than 50%.\(^1\)

Treatment options for arterial stenosis include angioplasty, covered stent placement in selected cases, and surgical revascularization.\(^8\) Early treatment with revascularization preserves graft function and often prevents retransplantation (►Fig. 11).

Pancreatic Transplant Vein Thrombosis

Venous thrombosis is the most common cause of early technical pancreatic transplant failure (70%).\(^8\) Early thrombosis may be associated with acute or hyperacute rejection. However, the majority (60%) of grafts lost to thrombosis are histopathologically normal.

The etiology is thought to be due to relative stasis caused by compression by a perianastomotic fluid collection, due to phlebitis related to pancreatitis, or because of the shift in organ position, leading to stretching or twisting of the venous anastomosis.\(^8\)

Given that pancreas grafts are predisposed to thrombosis, some propose routine postoperative anticoagulation.\(^4\) Meticulous surgical technique and rigorous avoidance of the transplant organ damage are considered to be more effective methods to decrease the incidence of early thrombosis.\(^8\)

Endovascular treatments of pancreas transplant venous thrombosis include thrombolysis, mechanical thrombectomy, and deployment of metal stents for anastomotic stenosis or kinks (►Fig. 13).\(^8\)

Pancreatic Transplant Arteriovenous Fistula Embolization

An arteriovenous fistula (AVF) is most commonly the consequence of biopsy of the transplanted allograft when the walls of both artery and vein are iatrogenically lacerated.\(^1\) It, however, can be iatrogenic soon after pancreatic transplantation, as in our case (►Fig. 14).

At duplex US, an AVF is identified as a focal area of aliasing involving a high-velocity low-resistance feeding artery and a pulsatile “arterialized” draining vein.\(^8\) Dual-phase (arterial and portal venous) CT helps in the characterization and anatomical localization of these vessels.

AVFs may be associated with regional areas of transient parenchymal enhancement on contrast-enhanced CT/MRI. Large AVFs may cause graft ischemia and dysfunction due to arterial “steal” phenomenon.\(^1\) They are usually treated with transarterial embolization.
Role of Interventional Radiology in the Management of Pancreatic Pathologies

Salahia et al.

Journal of Gastrointestinal and Abdominal Radiology ISGAR Vol. 3 No. 1/2020

Fig. 10 A 26-year-old female who underwent pancreatic transplantation 4 months previously presented with a firm mass in the right iliac fossa. (A) Computed tomographic angiography (B) digital subtraction angiography show right external iliac artery (EIA) occlusion (green arrow) shortly after Y graft. EIA reforms at the level of the inguinal ligament (yellow arrow). Note that the pancreatic transplant arterial anastomosis is widely patent, and so are both branches (blue arrows). This was treated with a prosthetic vascular graft (not shown).

Fig. 11 A 31-year-old male who underwent pancreatic and kidney transplant 4 years previously was admitted with urinary tract infection, sepsis, and right iliac fossa pain. (A) Coronal maximum intensity projection reformatted CT (computed tomography) shows occluded Y graft (green arrow) and no enhancement of the pancreas. (B, C) The patient underwent angioplasty and stent deployment.

Nonvascular Interventions on the Transplanted Pancreas

Due to the lack of consistent clinical symptoms or markers for rejection, pancreatic biopsies have become the standard method in diagnosing transplant rejection. The biopsy techniques are either through cystoscopy or by percutaneously using US and/or CT guidance, with a reported success rate of 83%.87 Cystoscopic biopsies require general anesthesia and only allows biopsy of the pancreatic head.88

No major complications occurred in a series of 42 attempted percutaneous biopsies.87 However, there is a risk of causing vascular damage to the allograft, including AV fistulation.1

Similar to native pancreas percutaneous interventions, drainage of peripancreatic transplant collections can be attempted on the transplanted pancreas with US or CT guidance.
Fig. 12 A 38-year-old female with a previously failed pancreatic transplantation presented with acute hematuria and deranged clotting. (A) Abdominal CT (computed tomography) suggests active hemorrhage (yellow arrow) from the right common iliac artery (CIA) into the bladder through the transplanted pancreas’ duodenal pouch (green arrow). (B) Angiography confirms right CIA contrast extravasation. (C) This was treated with a covered stent.

Fig. 13 A 35-year-old female presented with severe hyperglycemia at day 5 following simultaneous pancreas-kidney transplantation. (A) Coronal oblique maximum intensity projection reformatted CT (computed tomography) shows a filling defect within the vein graft in keeping with nonocclusive thrombus (blue arrow). (B) Catheter venography confirms graft thrombus (yellow arrow). (C) This was treated with mechanical thrombectomy.

Fig. 14 (A) Axial CT (computed tomography) demonstrates an arteriovenous fistula (AVF) in the transplanted pancreas (yellow arrow). (B) Three-dimensional reconstruction of the AVF. IVC, inferior vena cava.
Conclusion

The anatomical location of the pancreas has meant that historically, pancreatic pathologies were treated by either major surgery or conservative means.

Image-guided percutaneous intervention for a wide range of pancreatic disease is now routine.

Vascular complications of pancreatic disease benefit from accurate diagnosis with modern imaging techniques and may require immediate treatment. Endovascular intervention for the treatment of arterial and venous peripancreatic pathology is demonstrably effective.

Ablative techniques from cancer are emerging and may help to alleviate the high morbidity and mortality associated with pancreatic cancer and its treatment.

Vascular complications of the transplanted pancreas can be severe and cause early technical pancreatic transplantation failure. Percutaneous pancreas transplant biopsy has a high success rate and is most accurate in diagnosing transplant rejection. Advances of endovascular interventions permit revascularization and may salvage the graft.

Conflict of Interest

None declared.

References

3 Aswani Y, Hira P. Venous complications of pancreatitis: a review. JOP 2015;16(1):20–24
10 Zhao K, Adam SZ, Keswani RN, Horowitz JM, Miller FH. Acute pancreatitis: revised Atlanta classification and the role of cross-sectional imaging. AJR Am J Roentgenol 2015;205(1):W32
31 Nardis P, IR management of pancreatitis: optimal drainage strategies. Presented at the Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Copenhagen, Denmark, September 16–20; 2017
51 Kwon H, Kim C, Jeon C. Isolated pancreaticoduodenal vein injury from blunt abdominal trauma successfully treated by endovascular treatment. Presented at the Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Copenhagen, Denmark, September 16–20; 2017
Role of Interventional Radiology in the Management of Pancreatic Pathologies  
Salahia et al.

Journal of Gastrointestinal and Abdominal Radiology ISGAR Vol. 3 No. 1/2020


76 Dezman R, Serša G, Seliskar A, et al. Percutaneous electrochemotherapy of the pancreas is feasible and safe in a porcine survival model. Presented at the European Conference on Interventional Oncology Amsterdam, the Netherlands April 8–11; 2019


